{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":49,"n_cols":5,"rows_kept":49,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[11,2,11,3],[15,2,15,3],[16,2,16,3],[19,2,19,3],[22,2,22,3],[22,4,22,5],[23,2,23,3],[23,4,23,5],[24,2,24,3],[24,4,24,5],[25,2,25,3],[26,2,26,3],[27,2,27,3],[28,2,28,3],[29,2,29,3],[30,2,30,3],[31,2,31,3],[42,2,42,3],[43,2,43,3],[46,2,46,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910743218003321"]
[null,null,"Autore",null,"Maity Sudarshan"]
[null,null,"Titolo",null,"Financial Inclusion and the Role of Banking System / / by Sudarshan Maity, Tarak Nath Sahu"]
[null,null,"Pubbl/distr/stampa",null,"Singapore : , : Springer Nature Singapore : , : Imprint : Palgrave Macmillan, , 2022"]
[null,null,"ISBN",null,"9789811660856"]
[{"$nulls":4},"9811660859"]
[{"$nulls":4},"9789811660849"]
[{"$nulls":4},"9811660840"]
[null,null,"Edizione",null,"[1st ed. 2022.]"]
[null,null,"Descrizione fisica",null,"1 online resource (238 pages)"]
[null,null,"Disciplina",null,"160.5"]
[null,null,"Soggetti",null,"Financial services industry"]
[{"$nulls":4},"Finance, Public"]
[{"$nulls":4},"Financial Services"]
[{"$nulls":4},"Public Finance"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Chapter 1: Introduction -- Chapter 2: Financial Inclusion in India - An Overview -- Chapter 3: Review of Literature -- Chapter 4: Data and Methodology -- Chapter 5: Analysis and Findings -- Chapter 6: Summary and Conclusion."]
[null,null,null,"Sommario/riassunto","Financial inclusion has become an important global agenda and priority for policymakers and regulators in many countries for sustainable long-term economic growth. This book provides a brief guideline about the financial inclusion and the role of banking system on it which help the banks as well as regulator to select an effective banking structure and efficient composition of different factors to best utilization of their devoted resources in the context of a developing economy. It also provides an understanding regarding the loopholes of the present financial inclusion system. This book is important for policymakers to frame suitable policies and programs to accelerate the pace of financial inclusion and to create a win-win situation. This book would help regulator along with other financial intermediaries to redesign financial strategic framework for achieving long term vision of financial inclusion drive i.e. inclusive growth. Sudarshan Maity is presently Deputy Director in the Directorate of Examination, The Institute of Cost Accountants of "]
[{"$nulls":4},"India. He has over 19 years of administrative experience in various industries. Tarak Nath Sahu is presently Associate Professor in the Department of Commerce, Vidyasagar University, Midnapore, West Bengal, India. He has over 14 years of postgraduate teaching and research experience. His specialization is in finance and financial markets and his research publications are in the area of stock market behavior, corporate finance, corporate governance, investor behavior etc."]
[null,"2.","Record Nr.",null,"UNINA9910506380003321"]
[null,null,"Autore",null,"Kim Daria"]
[null,null,"Titolo",null,"Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law / / by Daria Kim"]
[null,null,"Pubbl/distr/stampa",null,"Cham : , : Springer International Publishing : , : Imprint : Springer, , 2021"]
[null,null,"ISBN",null,"3-030-86778-1"]
[null,null,"Edizione",null,"[1st ed. 2021.]"]
[null,null,"Descrizione fisica",null,"1 online resource (310 pages)"]
[null,null,"Collana",null,"Munich Studies on Innovation and Competition, , 2199-7470 ; ; 16"]
[null,null,"Disciplina",null,"342.240662"]
[null,null,"Soggetti",null,"Information technology - Law and legislation"]
[{"$nulls":4},"Mass media - Law and legislation"]
[{"$nulls":4},"Medical laws and legislation"]
[{"$nulls":4},"Law - Europe"]
[{"$nulls":4},"Clinical medicine - Research"]
[{"$nulls":4},"Quantitative research"]
[{"$nulls":4},"IT Law, Media Law, Intellectual Property"]
[{"$nulls":4},"Medical Law"]
[{"$nulls":4},"European Law"]
[{"$nulls":4},"Clinical Research"]
[{"$nulls":4},"Data Analysis and Big Data"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references."]
[null,null,"Nota di contenuto",null,"PART ONE: Setting the Scene -- Introduction -- The Context and the Problem in Focus -- Secondary Analysis of Clinical Trial Data - A Primer -- PART TWO: Analysis de lege lata,- Legal Sources of Control over and Access to Clinical Trial Data under the EU Applicable Framework -- Implications of IPD Disclosure for Statutory Innovation Incentives PART THREE: Analysis de lege ferenda -- Defining the Intervention Logic of Access-To-Data Measures - A Problem Analysis -- Access to Clinical Trial Data as a Case on R&D Externalities - A Theoretical Framework -- IPD as a Research Resource - Exclusively Controlled or Readily Accessible? -- Evaluating Legislative Options -- Final Conclusions and the Outlook."]
[null,null,null,"Sommario/riassunto","This book draws a unique perspective on the regulation of access to clinical trial data as a case on research and knowledge externalities. Notwithstanding numerous potential benefits for medical research and "]
[{"$nulls":4},"public health, many jurisdictions have struggled to ensure access to clinical trial data, even at the level of the trial results. Pro-access policy initiatives have been strongly opposed by research-based drug companies arguing that mandatory data disclosure impedes their innovation incentives. Conventionally, access to test data has been approached from the perspective of transparency and research ethics. The book offers a complementary view and considers access to individual patient-level trial data for exploratory analysis as a matter of research and innovation policy. Such approach appears to be especially relevant in the data-driven economy where digital data constitutes a valuable economic resource. The study seeks to define how the rules of access to clinical trial data should be designed to reconcile the policy objectives of leveraging the research potential of data through secondary analysis, on the one hand, and protecting economic incentives of research-based drug companies, on the other hand. Overall, it is argued that the mainstream innovation-based justification for exclusive control over the outcomes of research and development can hardly rationalise trial sponsors’ control over primary data from trials. Instead, access to such data and its robust analysis should be prioritised."]